Morgan Stanley’s Insys Therapeutics, Inc. INSY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-125,832
Closed -$580K 6883
2019
Q1
$580K Buy
125,832
+68,188
+118% +$323K ﹤0.01% 4463
2018
Q4
$202K Sell
57,644
-10,600
-16% -$73.7K ﹤0.01% 5283
2018
Q3
$688K Sell
68,244
-14,752
-18% -$118K ﹤0.01% 4795
2018
Q2
$601K Buy
82,996
+7,590
+10% +$52.9K ﹤0.01% 4971
2018
Q1
$455K Sell
75,406
-16,844
-18% -$139K ﹤0.01% 5059
2017
Q4
$888K Sell
92,250
-88,657
-49% -$580K ﹤0.01% 4618
2017
Q3
$1.61M Buy
180,907
+44,115
+32% +$455K ﹤0.01% 4072
2017
Q2
$1.73M Buy
136,792
+2,416
+2% +$28.6K ﹤0.01% 3930
2017
Q1
$1.41M Sell
134,376
-8,598
-6% -$91.6K ﹤0.01% 4114
2016
Q4
$1.31M Sell
142,974
-13,918
-9% -$157K ﹤0.01% 4257
2016
Q3
$1.85M Buy
156,892
+36,156
+30% +$550K ﹤0.01% 3555
2016
Q2
$1.56M Sell
120,736
-64,592
-35% -$941K ﹤0.01% 3628
2016
Q1
$2.96M Buy
185,328
+41,942
+29% +$797K ﹤0.01% 3001
2015
Q4
$4.11M Sell
143,386
-40,395
-22% -$1.12M ﹤0.01% 2865
2015
Q3
$5.23M Buy
183,781
+128,871
+235% +$4.74M ﹤0.01% 2621
2015
Q2
$1.97M Sell
54,910
-106,138
-66% -$3.31M ﹤0.01% 3637
2015
Q1
$4.68M Sell
161,048
-392,100
-71% -$10.4M ﹤0.01% 2817
2014
Q4
$11.7M Buy
553,148
+458,228
+483% +$9.06M ﹤0.01% 1917
2014
Q3
$1.84M Sell
94,920
-224,000
-70% -$3.52M ﹤0.01% 3513
2014
Q2
$4.98M Sell
318,920
-96,124
-23% -$1.55M ﹤0.01% 2672
2014
Q1
$8.6M Sell
415,044
-193,380
-32% -$3.84M ﹤0.01% 2076
2013
Q4
$7.85M Buy
608,424
+170,811
+39% +$2.37M ﹤0.01% 2146
2013
Q3
$5.1M Buy
437,613
+389,436
+808% +$3.2M ﹤0.01% 2405
2013
Q2
$222K Buy
+48,177
New +$177K ﹤0.01% 4784

Other funds holding INSY

Morgan Stanley's INSY Position: Q2 2019 in Review

Morgan Stanley sold out of Insys Therapeutics, Inc. (INSY) in Q2 2019, closing a stake of 125,832 shares — an estimated $580K sold.

Morgan Stanley first reported a position in INSY in Q2 2013 and held it in 24 quarters. The position peaked at $11.7M in Q4 2014. 16 funds tracked by Wall St. Rank hold INSY as of Q2 2019.

  • Morgan Stanley reported no remaining Insys Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Morgan Stanley sold 125,832 Insys Therapeutics, Inc. shares in Q2 2019, an estimated $580K.
  • Morgan Stanley first reported a position in Insys Therapeutics, Inc. in Q2 2013 and held it in 24 quarters.
  • Morgan Stanley's Insys Therapeutics, Inc. position peaked at $11.7M in Q4 2014.
  • 16 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2019.

Based on Morgan Stanley's 13F filing for Q2 2019, filed 14 Aug 2019.